An overview of QT interval assessment in safety pharmacology.

about

Comprehensive analyses of ventricular myocyte models identify targets exhibiting favorable rate dependence

P2860

Q28541597-651B4208-202D-4C93-811A-86DB7F361FFD

P2860

An overview of QT interval assessment in safety pharmacology.

Item

http://www.wikidata.org/entity/Q38112653

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

An overview of QT interval assessment in safety pharmacology.

@en

type

Item

label

An overview of QT interval assessment in safety pharmacology.

@en

prefLabel

An overview of QT interval assessment in safety pharmacology.

@en

P1476

An overview of QT interval assessment in safety pharmacology.

@en

P2093

Guillaume Froget

http://www.w3.org/2001/XMLSchema#string

Philippe Guillaume

http://www.w3.org/2001/XMLSchema#string

Sonia Goineau

http://www.w3.org/2001/XMLSchema#string

P2860

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome

K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current

Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey.

Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization.

Class 3 antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment

Preclinical cardiovascular risk assessment in modern drug development.

The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?

P304

Unit 10.7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/0471141755.PH1007S61

http://www.w3.org/2001/XMLSchema#string

P478

Chapter 10

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23744709

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

An overview of QT interval assessment in safety pharmacology.

about

P2860

P2860

An overview of QT interval assessment in safety pharmacology.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921